This small trial concerns a specified thymosin beta-4 ophthalmic preparation. Its eye measurements must not be mistaken for an equal number of independently enrolled people. Primary report
Trial snapshot
Nine patients with severe dry eye participated in a randomized, double-masked phase 2 comparison of RGN-259 eye drops with vehicle. Treatment lasted 28 days, followed by 28 days of follow-up. At day 56, the report describes improvements in ocular discomfort and corneal staining relative to vehicle, with 12 active-treatment eyes and six control eyes represented. The registration is NCT01393132, a different study from NCT01387347. Primary report
Our appraisal: identify the unit of analysis
Two eyes from one person share biological and environmental influences. Our full-paper review would therefore ask how the analysis handled measurements within a person. That question is not a claim that the investigators used an incorrect method; it is a necessary check before interpreting precision.
An invented analogy makes the issue clearer: measuring both hands of ten people yields twenty hand measurements, not twenty independent people. Extra measurements can be valuable, but they do not automatically double the amount of independent information.
Follow-up and formulation boundaries
Keep the last treatment day separate from later assessment days. A post-treatment observation can be important, but the exact interval should remain visible. It should not become a claim about an indefinite effect.
The preparation and route also belong in the evidence statement. Results from an ophthalmic formulation cannot automatically validate a differently formulated research material, a systemic route, or an unrelated tissue-repair claim. A familiar peptide name does not remove those differences.
For release review, verify which outcomes and time points were prespecified, the handling of correlated eye data, baseline severity, missing visits, and the complete adverse-event account.
Frequently asked questions
Were eighteen patients enrolled?
No. The report enrolled nine patients and describes eighteen eyes.
Was the comparator untreated observation?
No. It was vehicle control in a masked trial.
Was day 56 still part of the treatment period?
It followed the 28-day treatment period.
Does this trial validate products labeled TB-500?
No. Equivalence of a separate material cannot be inferred from a label.
Does the page recommend putting research material in the eye?
No. The experimental formulation is not a preparation guide.
Can this small trial settle long-term safety?
No. Its size and observation period limit that inference.
Why have a separate record for this study?
Its registration, sample, and severe-dry-eye setting differ from the other published ophthalmic trial.